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Abstract: This review summarizes the key findings of 14 clinical trials in which Galectin-3 
was assessed as a biomarker of heart failure. In addition, most relevant information available 
about Galectin-3 biology generated in in vitro and in vivo research is discussed in the context 
of heart failure.
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Introduction
Heart failure (HF) is a deleterious condition with an estimated prevalence of about 
1%–2% and is responsible for about 1%–2% of all health care spending in the Western 
world. HF biomarkers are of increasing importance for both physicians and preclini-
cal researchers. Quantification of biomarkers is a valuable tool in therapy monitoring, 
contributes to the prediction of clinical outcome, and can play a key role in patient 
stratification. This review summarizes the most relevant scientific knowledge that has 
accumulated so far on Galectin-3 (Gal-3) as a biomarker in HF.
First, the literature on the role of Gal-3 in different physiological and pathophysi-
ological conditions beyond cardiovascular diseases is reviewed to give the reader a 
comprehensive overview of the biological function of the lectin. Following this, the 
most important findings made in Gal-3 knockout mice are summarized. Since the most 
recent review on the role of Gal-3 in HF was published several years ago and various 
additional clinical studies assessing its utility for the management of cardiovascular 
disease have been published since, an update on this topic is urgently needed. Finally, 
14 clinical studies are summarized and the implications of their results assessed for 
clinical practice.
It is hoped that this review will provide the basis for the planning of further investi-
gations of Gal-3 in future clinical trials in its summarizing of the most relevant current 
knowledge about this biomarker in the context of cardiovascular diseases.
Molecular background and function of Gal-3
Gal-3 (also known as Mac-2, CBP-35, L29, LBP, or eBP) belongs to the family of 
β-galactoside-binding proteins with a preference for lactose and N-acetyllactosamine.1 
The human LGALS3 gene, which is located on chromosome 14, codes for a 250-amino 
acid protein with a molecular weight of 29–36 kDa.2 Gal-3 binds to a wide array of 
extracellular matrix proteins such as tenascin, fibronectin, and laminin due to its 
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carbohydrate recognition domain and collagen-like protein 
domains. There are a number of cell types that express 
Gal-3, including neutrophils, macrophages, mast cells, 
fibroblasts, and osteoclasts. Gal-3 has been detected in the 
lung, stomach, colon, uterus, and ovary.3 As Gal-3 lacks a 
signal sequence, which is essential for the classical secretory 
pathway, it is mainly found in the cytoplasm but can also be 
detected within the nucleus, as the first eleven amino acids 
serve as a nuclear localization domain.4 However, Gal-3 can 
be secreted via nonclassical pathways.5 Nuclear Gal-3 has 
the ability to alter gene expression through direct interaction 
with or stabilization of transcription factors and by regulation 
of nuclear pre-messenger (m) RNA splicing.6–8 A compre-
hensive overview of the biological functions of Gal-3 in the 
nucleus can be found elsewhere.9
In the cytosol, Gal-3 inhibits apoptosis, controls survival, 
and regulates exocytosis by interacting with a broad range 
of cytosolic proteins.
Though Gal-3 cannot be secreted via the classical endo-
plasmic reticulum–Golgi pathway, the lectin is abundant 
in different extracellular compartments, such as in serum, 
on cell surfaces, and in the extracellular matrix.5,10,11 It is 
postulated that after a heat shock protein-mediated Gal-3 
accumulation at the cytoplasmic side of the plasma mem-
brane, the lectin is secreted in an ectocytotic process.12 This 
hypothesis is supported by the observation that dendritic 
cell-derived exosomes contained Gal-3 protein.13 It was 
suggested that enzymatic breakdown of the exosome by, for 
example, members of the phospholipase family, leads to the 
release of Gal-3 from its transporter vesicles.5
After secretion, Gal-3 exhibits multiple autocrine and 
paracrine properties. Gal-3 activates neutrophils, mast, and 
T-cells, regulates cell adhesion, induces apoptosis, and pro-
vides angiogenic signals.14–18 Depending on the cell type and 
the balance between intracellular and extracellular Gal-3 in 
a biological system, Gal-3 can inhibit or induce cell growth 
and differentiation. A comprehensive review of the literature 
regarding physiological properties of nuclear, cytolsolic, and 
extracellular Gal-3 is beyond the scope of this manuscript 
(see Dumic et al for further details19).
Besides its autocrine and paracrine properties, Gal-3 
plays an important role in the defense against pathogens. 
Gal-3 enhances pro-inflammatory signals by being chemo-
tactic to macrophages and monocytes, mediating adhesion 
of neutrophils, inducing release of pro-inflammatory factors 
from white blood cells and mast cells, and participating in 
the phagocytic clearance of apoptotic neutrophils by mac-
rophages.20–23 Furthermore, Gal-3 directly interacts with 
galactoside-containing glycoconjugates on the surface of 
pathogens. It has been shown that Gal-3 recognizes and binds 
to Streptococcus pneumonia, Escherichia coli, Pseudomonas 
aeruginosa, Candida albicans, Mycobacterium tuberculosis, 
and different Salmonella strains.24–28 An overview about the 
molecular background and function of Gal-3 is displayed 
in Figure 1.
Gal-3 in disease models
In the myocardium, the Gal-3 expression level is almost 
undetectable in cardiomyocytes, whereas cardiac fibroblasts 
express higher levels of this carbohydrate-binding lectin.29 
Recently, Schroen et al identified strong upregulation of 
Gal-3 mRNA in a rat model of renin-dependent hyperten-
sion.30 In further studies, Sharma et al found that myocardial 
Gal-3 was increased in those animals, which progress to HF.29 
They also found that infusion of Gal-3 into the pericardium 
induced myocardial collagen deposition and remodeling. 
A profibrotic effect of Gal-3 was also identified for hepatic 
fibrosis and myofibroblast differentiation and in a rat model 
treated by the naturally occurring anti-fibrotic peptide 
N-acetyl-seryl-aspartyl-lysyl-proline.31,32 In addition, a very 
recent publication illustrates the role of Gal-3 as a mediator 
of aldosterone-induced vascular fibrosis.33 The investigators 
show that: Gal-3 protein expression is increased in a dose-
dependent manner on aldosterone treatment in cultured rat 
vascular smooth muscle cells within 24 hours, overexpression 
of recombinant human Gal-3 induced a 1.6-fold increase of 
collagen type I (Coll-I) deposition in rat vascular smooth 
muscle cells, and aldosterone-induced Coll-I deposition can 
be blocked by either Gal-3 neutralizing small interfering 
RNA (siRNA) or chemical inhibitors of Gal-3 carbohydrate-
binding activity. Finally, the authors of that study confirmed 
these in vitro data by showing that aldosterone treatment 
increased aortic Gal-3 and Coll-I expression in wild-type 
(WT) mice, whereas Gal-3 knockout (Gal-3–/–) mice are 
protected against these alterations. Thus, there is ample 
experimental evidence from different cardiovascular disease 
models that Gal-3 might be a biomarker involved in fibro-
sis induction and myocardial remodeling.34
Besides this, the active role of Gal-3 in the development 
of tissue fibrosis is underlined by the additional observa-
tions made in Gal-3−/− mice in different disease models. 
Recently, it has been shown that Gal-3 mRNA and protein 
are upregulated in a mouse model of progressive renal 
fibrosis.35 The same study demonstrated that depletion of 
Gal-3 protects against renal fibrosis in this disease model. 
Notably, in the mouse model of unilateral ureteric obstruction 
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(UUO) used, the depletion of macrophages also led to a 
significantly reduced activation of myofibroblasts, which 
are key players in fibrotic disorders, and reduced collagen 
expression. Importantly, the disruption of the Gal-3 gene 
affected neither macrophage recruitment to the affected 
kidney nor the secretion of pro-inflammatory cytokines from 
macrophages after interferon-gamma/ lipopolysaccharide 
stimulation. In addition, the absence of endogenous Gal-3 
did not alter transforming growth factor (TGF)-β expres-
sion or TGF-β-receptor downstream signaling via Smad2/3. 
Considering these observations, the authors of that study 
concluded that Gal-3 secretion by macrophages is critical 
for the development of renal fibrosis, at least in the mouse 
model of UUO used.
Further evidence for the involvement of Gal-3 in the onset 
and progression of fibrotic disorders is supplied by work of 
the same research group performed on a carbon tetrachloride 
(CCl
4
)-induced liver injury model in mice.31 Henderson and 
colleagues showed that disruption of the Gal-3 gene inhibits 
myofibroblast activation and pro-collagen I expression though 
all investigated indicators of CCl
4
-induced liver injury, such 
as inflammation, and TGF-β expression showed no difference 
between Gal-3–/– and WT mice. Application of Gal-3 siRNA in 
WT mice on CCl
4
-induced liver injury supported the key role 
of Gal-3 in induction and progression of liver fibrosis.
The effect of Gal-3 disruption on different disease-specific 
readouts has been assessed in various disease models such 
as atherosclerosis, ischemic brain injury, during helminthic 
infection, in acetaminophen-induced hepatotoxicity, asthma, 
and in different infectious diseases.36–44
Gal-3 in cardiovascular disease
In recent years, a growing number of clinical studies examin-
ing the utility of Gal-3 as a biomarker for the management of 
cardiovascular disease have been published. The main find-
ings from these studies are summarized in the following.
Clinical trials evaluating Gal-3 in cardiovascular dis-
ease patients can be categorized into four groups: those 
(1) assessing utility of the serum/plasma concentration of the 
lectin for diagnosis, (2) studying stratification for therapy, 
(3) monitoring therapy response, and (4) predicting short- and 
long-term morbidity and mortality.
Diagnosis
In 2006, van Kimmenade et al45 evaluated the utility of Gal-3 
for diagnosis of HF in 599 patients of the previously reported 
N-terminal Pro-BNP Investigation of Dyspnea in the Emer-
gency Department (PRIDE) study.46 Gal-3 was not correlated 
to the New York Heart Association (NYHA) Functional Clas-
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Figure 1 Overview about molecular background and function of Galectin-3.
Note: Chromosomal localization of human LGALS3 gene, potential localization of Galectin-3 protein and the biological properties of the lectin are depicted.
Abbreviations: aa, amino acid; TF, transcription factor; Bcl-2, B-cell lymphoma 2; APO-1, accumulation of photosystem 1; AiP-1, actin interacting protein 1; K-Ras, v-Ki-ras2 
Kirsten rat sarcoma viral oncogene homolog.
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in identifying HF within the cohort than amino terminal pro-
brain natriuretic peptide (NT-proBNP) (receiver operating 
characteristic [ROC] curve analysis for NT-proBNP and 
Gal-3: 0.94, P , 0.0001 and 0.72, P , 0.0001, respectively). 
The optimal cutoff for 80% specificity and 52% sensitivity 
was 6.88 ng Gal-3/mL. The area under the curve (AUC) 
difference between NT-proBNP and Gal-3 was highly sig-
nificant (P , 0.0001). Furthermore, there was no significant 
difference in median concentration of Gal-3 between ischemic 
and nonischemic HF patients or between patients displaying 
systolic versus non-systolic disease. Although Gal-3 did not 
outperform NT-proBNP in the diagnosis of HF, the assess-
ment of this biomarker can complement the information 
gained by the natriuretic peptide. In any case, Gal-3 has the 
potential to predict outcomes for HF patients (see “Prediction 
of clinical outcome” later in this paper).
Patient stratification
Recently, plasma Gal-3 concentrations were assessed in 
patients with chronic HF upon treatment with rosuvastatin in 
a subpopulation of the Controlled Rosuvastatin Multinational 
Trial in Heart Failure (CORONA) trial.47 The purpose of this 
investigation was to assess whether patients with ischemic 
systolic HF displaying lower plasma Gal-3 levels benefit 
from statin therapy. Therefore, Gal-3 concentration was 
evaluated in 1492 patients, of whom 411 suffered nonfatal 
stroke, myocardial infarction, or cardiovascular death during 
a medium follow-up of approximately 33 months. Although 
rosuvastatin did not show a significant effect on primary end-
points (see Kjekshus et al48 for overall results of CORONA), 
subjects with plasma Gal-3 levels less than or equal to the 
median receiving statin therapy had a 30.4% lower event rate 
compared with placebo-treated patients of the same group 
(P = 0.019).48 Interestingly, patients with Gal-3 levels less 
than or equal to the median and NT-proBNP levels below 
102.7 pmol/L exhibited particularly low cardiovascular event 
rates on rosuvastatin therapy (hazard ratio 0.33; confidence 
interval 0.16–0.67; P = 0.002). Conversely, no benefit of 
rosuvastatin therapy was observed in patients with Gal-3 
levels greater than the median.
In a sub-study including approximately 30% of patients 
recruited to the large Valsartan Heart Failure Trial (Val-HeFT), 
the response to valsartan treatment was evaluated in patients 
displaying Gal-3 levels above or below the median.49–51 As 
with rosuvastatin in the CORONA trial, valsartan signifi-
cantly reduced hospitalization for HF in patients with low 
baseline Gal-3 levels. In contrast, patients with Gal-3 levels 
above the median did not benefit from valsartan treatment.
Although the data generated in the CORONA and Val-
HeFT trial and the conclusions drawn from the results are of 
importance to further understand the usefulness of Gal-3 as a 
biomarker of cardiovascular disease, these findings, at least 
currently, have no implications for clinical practice.
A further trial to investigate whether Gal-3 levels can be 
applied to select patients for a certain therapy was performed 
by Stein. In a Multicenter Automatic Defibrillator Implanta-
tion with Cardiac Resynchronization Therapy (MADIT-CRT) 
sub-study, the investigators examined whether early stage 
HF patients could be selected and prioritized for cardiac 
resynchronization therapy (CRT) based on plasma Gal-3 
concentrations.52 The study revealed that all patients benefited 
from the CRT regardless of their Gal-3  levels. However, 
patients displaying high Gal-3 levels  benefited more from 
CRT, which is not surprising since higher Gal-3 levels mir-
ror higher disease stage and worse prognosis (see “Predic-
tion of clinical outcome”). Further studies in CRT patients 
are required to verify Stein’s hypothesis that Gal-3 might be 
used to prioritize patients for this kind of intervention.
Stein’s findings are in line with the recent findings in CRT 
patients in the Cardiac Resynchronization in Heart Failure 
(CARE-HF) study.53 Patients clearly benefited from CRT, 
as therapy was associated with improved outcome, which 
was defined as survival, development of  worsening HF, left-
ventricular ejection fraction (LVEF) .35%, and NT-proBNP 
levels , 1000 pg/mL. However, baseline Gal-3 concentrations 
did not predict response to CRT.
Therapy monitoring
The ability to detect beneficial effects of a (pharmaco)therapy 
on indices of cardiovascular disease early is important not 
only to the physician in their daily practice but also to study 
teams investigating effects of potential new chemical or 
biological entities. A biomarker indicating the modulation 
of pathomechanisms by an active substance on the molecular 
level before functional parameters of the heart change – such 
as ejection fraction (EF) or global longitudinal strain – has 
the potential to accelerate the development and approval of 
new drugs and may help to optimize management of cardio-
vascular disease.
To assess the utility of Gal-3 as a response-to-treatment 
biomarker, the longitudinal assessment of this factor on 
(pharmaco)therapy is key. Unfortunately, most published 
studies have evaluated Gal-3 concentrations only at baseline. 
However, the ability of Gal-3 to predict response to treatment 
was investigated in terminal HF patients needing mechani-
cal circulatory support.54 In 55 patients with deteriorating 
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HF, Gal-3 was measured pre- and postimplantation of a 
left-ventricular assist device (LVAD), total artificial heart 
(TAH), or heart and compared with levels in apparently 
healthy blood donor controls (mean 4.07 ng/mL). Gal-3 
was significantly increased in HF patients (mean 11 ng/mL). 
Although there is ample experimental evidence indicating 
that Gal-3 is involved in development of fibrosis, mechani-
cal unloading of the heart (n = 40) or removal of the fail-
ing ventricles (n = 15) did not reduce the plasma levels of 
Gal-3.29,31,32,54 However, patients who did not survive LVAD 
support had significantly elevated plasma concentrations of 
Gal-3 at the time of LVAD implantation compared with those 
patients who could be bridged to transplantation.54 These data 
were recently confirmed by the same group of investigators 
in a larger cohort of 151 ventricular assist device (VAD) 
patients.55 The ROC curve analysis for death under VAD 
support provided comparable data to previous reports with 
an AUC for Gal-3 of 0.64 (P = 0.009).
These data have raised the question of whether plasma 
Gal-3 might be a useful biomarker for prediction of mortal-
ity in patients with severe HF needing VAD, TAH, or heart 
transplant. Therefore, very recently, Erkilet et al investigated 
plasma Gal-3 levels as well as myocardial Gal-3 mRNA and 
protein expression in advanced HF patients needing VAD 
support.56 Plasma Gal-3 concentrations were significantly 
elevated in the group of 175 deteriorating HF patients com-
pared with the 98 blood donor controls. Consistent with 
previous findings,54 unloading of the heart did not influence 
plasma Gal-3 levels within the first 30 days after device 
implantation. Gal-3 mRNA and protein were detectable in 
the failing myocardium, but, interestingly, these did not cor-
relate with its plasma concentration. This raises the question 
as to whether the failing myocardium is the primary source 
of elevated plasma Gal-3. Finally, Gal-3 did not provide suf-
ficient discrimination for prediction of outcome after VAD 
implantation.
In the CARE-HF study, response of Gal-3 to CRT was 
evaluated in 260 HF patients with NYHA class III or IV.53 
Although patients benefited from CRT, no significant effect 
of therapy on Gal-3 levels was recorded within 18 months. 
In contrast, the pressure/volume overload biomarker NT-
proBNP mirrored positive effects of resynchronization.
The observation that Gal-3 does not mirror therapy 
response, made in the two aforementioned studies, was 
confirmed recently in the Deventer-Alkmaar heart failure 
(DEAL-HF) study.57 In 182 NYHA class III and IV HF 
patients there was no correlation between change in 
Gal-3 levels over time (3 months to baseline and 1 year to 
baseline) and change in left-ventricular end-diastolic volume, 
a measure of left-ventricular remodeling.
Considering these observations, it becomes clear there 
is no evidence to date that either serum or plasma Gal-3 
concentration is a useful tool with which to monitor therapy 
response.
Prediction of clinical outcome
Short-term outcome
The utility of Gal-3 in predicting clinical outcome was 
assessed, for example, in patients with acute dyspnea pre-
senting to the emergency department in the PRIDE study.47 
As already mentioned, Gal-3 concentration was found to be 
significantly increased in the plasma of HF patients in this 
study. During the follow-up at 60 days, 29% of the 209 acute 
HF patients showed recurrent HF and 8% died. Median Gal-3 
levels were significantly higher in patients who had recur-
rent HF or died within 60 days. The AUC of a ROC curve 
for the 60-day mortality or recurrent HF for Gal-3 was 0.74 
(P , 0.0001) versus 0.67 (P , 0.009) for NT-proBNP. Based 
on this, the authors defined the cutoff for the prediction of 
60-day mortality as 9.42 ng/mL Gal-3 (75% sensitivity, 
56% specificity). The adjusted multivariate analysis revealed 
that Gal-3 was superior to NT-proBNP. The rate of death or 
recurrent HF was highest in patients with combined elevated 
Gal-3 and NT-proBNP (.5562 pg/mL). Thus, although NT-
proBNP was superior in diagnosing HF in this study, Gal-3 
was a stronger predictor of short-term mortality.
Mid-term outcome
The first evidence for a prognostic value of Gal-3 in patients 
with chronic HF came from the Coordinating study evaluat-
ing Outcomes of Advising and Counseling in Heart failure 
(COACH) study in which 592 patients with mild, moderate, 
and severe forms of the disease were investigated during a 
mean follow-up of 18 months.58 In 2011, the same group 
published an extended data package generated from this 
trial.59 The more recent publication includes data analysis 
of findings from the study of patients assigned to one of two 
groups: heart failure with reduced ejection fraction (HFREF) 
and heart failure with preserved ejection fraction (HFPEF). 
Individuals with a LVEF . 40% were assigned to the HFPEF 
group. The primary outcome measure of this study was a 
composite of all-cause mortality and HF hospitalization. This 
is one of the few studies so far that has analyzed Gal-3 not 
only at baseline but also in approximately 50% of patients 
after 6 months. The hazard ratio to reach the primary out-
come increased constantly from the first to the fourth serum 




Clinical utility and prognostic value of Galectin-3 in heart failure
Research Reports in Clinical Cardiology 2013:4
Gal-3 quartile. Changes of serum Gal-3 levels during first 
6 months of the study did not add prognostic information to 
the baseline value. However, interestingly, while absolute 
Gal-3 levels did not differ between HFPEF and HFREF 
patients, the prognostic value of Gal-3 was more pronounced 
in HFPEF patients than in individuals with reduced EF. It 
was found that the same increase of Gal-3 levels in patients 
with HFPEF and HFREF was associated with a significantly 
stronger risk for reaching the primary outcome in patients 
with HFPEF. Taken together, these results show that baseline 
serum Gal-3 concentration has independent prognostic value 
for the endpoint all-cause mortality and HF hospitalization, 
even when corrected for established risk factors.
The predictive power of serum Gal-3 concentration 
was also assessed in HF patients (NYHA class III or IV) 
with evidence of left-ventricular systolic dysfunction and 
cardiac dyssynchrony as indicated by electrocardiogram or 
echocardiography in the CARE-HF study.53 Gal-3 was deter-
mined in serum at baseline and after 3 and 18 months. In 
this study, baseline Gal-3 was associated with death or HF 
hospitalization. The odds ratio (OR) for these endpoints in 
patients displaying a Gal-3 level of .30 ng/mL was 2.05.
The ability of Gal-3 to predict development of HF in 
patients suffering from acute coronary syndrome (ACS) 
was evaluated in a subgroup of the Pravastatin or Atorva-
statin Evaluation and Infection Therapy – Thrombolysis In 
Myocardial Infarction 22 (PROVE-IT TIMI 22) trial.60 In 
this trial, 100 ACS patients were followed up for a mean 
duration of 2 years for the development of HF. Serum Gal-3 
levels were increased in individuals who developed HF. 
Assessment of the unadjusted OR revealed a graded rela-
tionship between Gal-3 and the risk to develop HF. Patients 
in the second Gal-3 quartile (13.0–15.5 ng/mL) had an OR 
of 2, whereas patients in the fourth quartile (.19.2 ng/mL) 
had an OR of 3.9.
A subgroup analysis of the Heart Failure: A Controlled 
Trial Investigating Outcomes of Exercise TraiNing (HF-
ACTION) investigated the relationship between baseline 
plasma GAL-3 concentrations and all-cause hospitalization 
and all-cause mortality during a mean follow-up of 2.5 years 
in patients with chronic HF with an EF , 35%.61 The inves-
tigators found that Gal-3 was associated with higher NYHA 
class, higher creatinine, lower maximal oxygen consumption, 
and lower systolic blood pressure. Interestingly, in this study, 
there was only a modest correlation between NT-proBNP 
and Gal-3 levels. When grouping patients according to 
whether they were below or above medium level for each 
biomarker, there was discordance between both biomarkers 
in 36% of patients (292/815). However, there was a progres-
sively increased hazard for low NT-proBNP/high Gal-3, 
high NT-proBNP/low Gal-3, and high NT-proBNP/high Gal-3 
with regard to hospitalization-free survival.
Long-term outcome
The predictive value of Gal-3 was also analyzed in the 
recently published DEAL-HF study of 232 patients with 
chronic HF (NYHA class III–IV).62 During the follow-up 
of 6.5 years, 42% of recruited patients died. Approximately 
50% of patients displayed a Gal-3 level above the upper 
normal level of 17.7 ng/mL. Plasma Gal-3 concentrations 
were significantly correlated with age and NT-proBNP levels. 
Interestingly, there was no correlation between EF or type of 
HF and Gal-3. Patients who died during the follow-up period 
exhibited significantly higher baseline Gal-3 levels than the 
survivors. By ROC curve analysis, the authors found an AUC 
of 0.612 (P = 0.004) for Gal-3 for mortality within the study 
population, which was comparable to NT-proBNP (AUC 
0.611). The highest product of sensitivity and specificity was 
found with 17.72 ng Gal-3/mL. Even after adjustment for 
the covariates age, sex, estimated glomerular filtration rate, 
and NT-proBNP, plasma concentration of Gal-3 remained a 
strong predictor of mortality.
A second publication presenting data from an extended 
follow-up of 8.7 ± 1 year confirmed and expanded the 
initial findings.57 Kaplan–Meier analysis revealed that 
Gal-3 was associated with mortality during the follow-up 
period. Mortality rate increased across the Gal-3 quartiles. 
Fortunately and in contrast to most other trials assessing 
Gal-3, in the DEAL-HF program, serum samples were 
acquired not just at baseline but also after 3 and 12 months. 
When assessing the longitudinal course of Gal-3 levels, the 
investigators found that a change in Gal-3 concentration 
was not associated with survival and did not predict change 
of the left-ventricular end-diastolic volume. Therefore, the 
authors concluded that serial measurement does not add 
any benefit to single-point assessment. It is of note that 
Gal-3 plasma concentrations were significantly associated 
with renal dysfunction, which is of relevance because HF 
is often accompanied by impaired renal function. This find-
ing is in line with the most recent findings of Erkilet and 
colleagues56 and the results of the COACH study59 which 
underlines that Gal-3 is not a heart-specific biomarker. As 
such, conclusions drawn from Gal-3 serum levels must 
always be considered in the context of comorbidities, as 
some of the prognostic power of this biomarker may be 
mediated by renal function. Although the authors of the 
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DEAL-HF study postulate that Gal-3 may potentially be 
used in the management of HF patients, the group provides 
no clear recommendation for the application of Gal-3 in 
clinical practice.62
Shah et al recently published data from 115 acutely 
decompensated HF patients, a subpopulation of the PRIDE 
study.45,63 Notably, Gal-3 was the strongest predictor of 
4-year mortality when compared by multivariate analysis 
including echocardiographic indices. Patients with Gal-3 
levels . 14.97 ng/mL had a hazard ratio of 5.5.
Finally, the relationship between Gal-3 and risk factors 
for cardiovascular disease as well as the predictive power of 
the lectin for cardiovascular and all-cause mortality were 
investigated in a large cohort of the Prevention of REnal 
and Vascular END stage disease (PREVEND) trial.64 The 
study recruited 7968 Caucasian individuals from the general 
population who were followed up for approximately 10 years, 
making this the largest study with the longest observation 
period investigating Gal-3 levels to date. Plasma Gal-3 con-
centrations were assessed at entry. The study found that Gal-3 
was correlated with age; median Gal-3 levels were higher in 
women; Gal-3 was correlated with various cardiovascular risk 
factors such as body mass index, blood pressure, serum lipids, 
and renal function – this correlation was more pronounced 
in females; and baseline Gal-3 was an independent predictor 
of all-cause mortality in the general population but not of 
cancer or cardiovascular mortality.
A brief description of each of the clinical trials summa-
rized in the present paper is presented in Table 1.
Discussion and future directions
“Biomarker” was defined by the National Institutes of Health 
in 2001 as “a characteristic that is objectively measured 
and evaluated as an indicator of normal biological process, 
pathogenic process or pharmacological response to a thera-
peutic intervention.”65 The appraisal of biomarker data can 
help address various challenges, such as early diagnosis of a 
disease, decision on the therapy most likely to be efficacious 
(personalized medicine), monitoring of response to interven-
tion, exclusion of patients most likely to show unintended 
therapeutic side effects, and prediction of patient outcome in 
both clinical trials and daily clinical practice. Further, bio-
markers are valuable tools supporting preclinical development 
through their use as indicators for efficacy or toxic/unintended 
effects of new chemical/biological  entities in preclinical 
disease models. Biomarkers that behave similarly in animal 
models and human patients also have the potential to become 
bridging tools between research and clinical development.
Based on its utility in these applications, the value of 
Gal-3 as a biomarker in HF can be assessed.
Support for decision-making  
in preclinical development
As Gal-3 was found to be strongly upregulated in a rat model 
of renin-dependent hypertension – especially in those ani-
mals that progressed to HF35 – the lectin might be a valuable 
disease and response-to-treatment biomarker in HF animal 
models. However, more data from other species, especially 
on treatment with already-approved drugs, are desirable.
Early diagnosis of disease
The capability of Gal-3 to indicate HF seems to be limited. 
Kimmenade et al showed in patients with dyspnea that Gal-3 
had a lower specificity and sensitivity than NT-proBNP 
to detect HF.46 Furthermore, Gal-3 did not correlate with 
NYHA class nor enable distinction between ischemic and 
nonischemic HF or patients displaying systolic or non-
systolic disease.
Decision on the most efficacious therapy 
(personalized medicine/patient selection)
Based on data published thus far, the utility of Gal-3 in 
patient/therapy selection cannot be assessed yet. Although 
response to treatment in patients displaying a baseline 
Gal-3 level below or above the mean has been assessed in 
statin, sartan, and cardiac resynchronization therapy, there 
still is no clear evidence that patients selected based on 
plasma Gal-3 levels are more likely to benefit from a certain 
therapy.
Monitoring of response to intervention
To date, there is no clear evidence that serum or plasma 
Gal-3 levels are useful in monitoring therapy response. This 
is underscored by the observation that mechanical unloading 
of the failing ventricle by VAD did not reduce serum Gal-3 
concentrations.54–56 Even in patients clearly benefiting from 
CRT, no significant reduction of Gal-3 levels was observed 
within 18 months.53 Furthermore, in NYHA class III and 
IV patients, no correlation was seen between changes in 
echocardiographic indices of left-ventricular remodeling and 
longitudinal Gal-3 levels.57
Exclusion of patients most likely to show 
unintended therapeutic side effects
As far as this author is aware, no studies addressing this issue 
have been performed so far.
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Prediction of patient outcome
Most reported studies have investigated the predictive 
value of baseline Gal-3 levels.45,47,51,59,60,61–64 Strong evidence 
has accumulated that Gal-3 is a strong predictor of short-,46 
mid-,53,58–61 and long-term mortality45,57,62–64 as well as HF-
associated hospitalization in different HF patient popula-
tions, including early51 and late-stage disease as well as 
HFPEF and HFREF.59 Furthermore, Gal-3 predicted 
development of HF after ACS.60
General considerations
Although the studies analyzed in this review are sub-studies 
of larger trials, more than 16,900 patients were characterized 
in terms of their Gal-3 levels in these investigations, which 
probably makes Gal-3 one of the best-described cardiovas-
cular biomarker candidates after brain natriuretic peptide 
and NT-proBNP. Nevertheless, at present, it is not clear how 
to translate these results into clinical guidelines for patient 
management. Compared with oncology, in which the use of 
biomarkers – for example, for patient selection – is already 
part of daily practice, the application of biomarkers, such 
as Gal-3, in cardiology is still in its infancy. Furthermore, 
Gal-3 is not a heart-specific biomarker. The lectin is also 
involved – for instance, in the development of experimental 
renal disease (see “Support for decision-making in preclinical 
development”) – and there are clear suggestions that Gal-3 
levels are correlated with the severity of renal dysfunction 
in HF patients.63
Moreover, it is of note that Gal-3 also seems to be an 
important player in the development, growth, and metasta-
sis of tumors. In contrast to the multiple studies that have 
investigated Gal-3 in cardiovascular diseases, little has 
Table 1 Clinical trials assessing Galectin-3





PRiDE Acute dyspnea Diagnosis of HF and 
short-term prognosis
60 d 599 BL van Kimmenade 
et al45
PRiDE Acute dyspnea Relationship between Gal-3 and 
cardiac structure (echocardiography)
4 y 115 BL Shah et al63
CORONA ischemic systolic 
HF
Utility of Gal-3 to predict response 
to rosuvastatin therapy
32.8 mth 1492 BL Gullestad et al47
CARE-HF Lv dysfunction and 
dyssynchrony
Association of Gal-3 with long-term 
Cv outcome upon CRT




COACH HFPEF and HFREF Predictive value of Gal-3 in HFPEF 
and HFREF
18 mth 592 BL de Boer 
et al59
MADiT-CRT Nonischemic early 
stage HF (EF , 30%)
Utility of Gal-3 to prioritize patients 
for CRT
2.4 y 1761 BL Stein52 
PROvE-iT  
TiMi 22
Unstable angina or 
myocardial infarction
Relationship between Gal-3 and 
development of HF on ACS
2 y 100 BL Grandin et al60
DEAL-HF Chronic HF (NYHA 
class iii–iv)
Prognostic value of Gal-3 6.5 y 232 BL Lok et al62
DEAL-HF Chronic HF (NYHA 
class iii–iv)
Utility of Gal-3 as marker of 
Lv remodeling and prognostic factor
8.7 y 240 BL, 3 mth, 
1 y
Lok et al57
val-HeFT HF (EF , 40%) Response to valsartan in patients 
with Gal-3 above or below mean
12 mth ∼1500 BL, 4 mth,  
12 mth
Anand i51
PREvEND Caucasian general 
population
Association between Gal-3 with 
Cv and general outcome
10 y 7968 BL de Boer et al64
HF-ACTiON Chronic HF (NYHA 
class ii–iv), (EF , 35%)
Association between Gal-3 with all-cause 
hospitalization/all-cause mortality
2.5 y 895 BL Felker et al61
Not applicable vAD, Htx, TAH Response of Gal-3 to unloading of heart 30 d 55 BL, 30 d Milting et al54
Not applicable vAD Predictive value of plasma Gal-3 for 
death on device. Myocardial Gal-3 
messenger RNA and protein expression
Ongoing 175 BL, 30 d Erkilet et al56
Abbreviations: BL, baseline Gal-3 was determined at study entry; CARE-HF, Cardiac Resynchronization in Heart Failure; COACH, Coordinating study evaluating 
Outcomes of Advising and Counselling in Heart failure; CRT, cardiac resynchronization therapy; CORONA, Controlled Rosuvastatin Multinational Trial in Heart Failure; 
Cv, cardiovascular; d, days; EF, ejection fraction; HF, heart failure; HF-ACTiON, Heart Failure: A Controlled Trial investigating Outcomes of Exercise TraiNing; HFREF, 
heart failure with reduced ejection fraction; HFPEF, heart failure with preserved ejection fraction; Htx, heart transplantation; L, longitudinal assessment of Gal-3; Lv, left 
ventricular; MADIT-CRT, Multicenter Automatic Defibrillator Implantation with Cardiac Resynchronization Therapy; mth, months; NYHA, New York Heart Association; 
PRiDE, N-terminal Pro-BNP investigation of Dyspnea in the Emergency Department; PROvE-iT TiMi 22, Pravastatin or Atorvastatin Evaluation and infection Therapy – 
Thrombolysis In Myocardial Infarction 22; TAH, total artificial heart; VAD, ventricular assist device; Val-HeFT, Valsartan Heart Failure Trial; y, years; PREVEND, Prevention 
of REnal and vascular END stage disease; DEAL-HF, Deventer-Alkmaar heart failure.
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been published so far on the utility of this biomarker in 
oncological indications. Although it is far beyond the scope 
of this manuscript to review the role of Gal-3 in oncology, 
it is worth noting that data recently published by de Boer 
et al showed that Gal-3 is a strong predictor of cancer 
mortality.64
Conclusion
A significant number of clinical studies investigating prop-
erties and utility of Gal-3 emphasis its role as a promising 
HF biomarker candidate. Nevertheless, more clinical studies 
investigating Gal-3 longitudinally, especially on therapy, are 
desirable. Future studies have to clearly demonstrate how 
individual Gal-3 levels can guide decision-making in daily 
clinical practice or during the drug-development process and 
thereby improve HF patient care.
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